FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HICKS KERRY R</u>					2. Issuer Name and Ticker or Trading Symbol TriSalus Life Sciences, Inc. [TLSI]					(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 08/10/2023						_	(give title	Other (s below)	pecify		
6272 W. 91ST AVENUE				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)											X Form filed by One Reporting Person Form filed by More than One Reporting					
WESTMINSTER CO 80031											Person					
(City) (State) (Zip)				R	Rule 10b5-1(c) Transaction Indication											
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				Transactior ite onth/Day/Y	Execution Date,		Code (Instr. 5)			ed (A) or tr. 3, 4 and	Beneficia Owned F	es Form ially (D) (Following (I) (I	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amo	nount (A) or (D)		Price	Reported Transact (Instr. 3 a	ion(s)		Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, To or Exercise (Month/Day/Year) if any		Code (ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expirat Date	tion	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$11.34	08/10/2023		A		35,000		(1)	08/09/2	2033	Common Stock	35,000	\$0.00	35,000	D	

Explanation of Responses:

1. The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on

Remarks:

/s/ Sean Murphy, Attorney-in-Fact for Kerry Hicks

08/14/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.